GCO12F CAR-T

A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma

What's the purpose of the trial?

This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
80
Last Updated
1 week ago
Patient Screener

Participating Centers

There are 8 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • AZD0120 is a study treatment that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize BCMA (a protein found on myeloma cells) more easily.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

GC012F

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.